Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics

被引:49
作者
Cauchetier, E
Deniau, M
Fessi, H
Astier, A
Paul, M
机构
[1] CHU Henri Mondor, Serv Pharm, Lab Pharmacotech, F-94010 Creteil, France
[2] CHU Henri Mondor, Parasitol Lab, F-94010 Creteil, France
[3] Univ H Poincare, Lab Pharm Clin, F-54000 Nancy, France
[4] Fac Pharm Claude Bernanrd, Lab Genie Pharmacotech & Biogalen, F-69000 Lyon, France
关键词
atovaquone; nanocapsules; PLA; PLAGA; PECL;
D O I
10.1016/S0378-5173(02)00556-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nanocapsules with atovaquone concentration of 1000 mug/ml were prepared according to the interfacial deposition technique using different polymers: poly-E-caprolactone (PECL), poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLAGA). The following characteristics of nanoparticles were determined: percentage of encapsulation of atovaquone, percentage of encapsulation of benzyl benzoate (BB), nanoparticle size, nanoparticle wall thickness, suspension pH, and in vitro stability. The different formulations showed similar characteristics: maximal percentage of encapsulation (100%), particle size of approximately 230 nm, neutral pH and wall thickness of approximately 20 nm. The type of polymer used was the main factor influencing stability, in decreasing order: PECL > PLA > PLAGA. No release of atovaquone or benzylbenzoate was noted with PECL nanoparticles over 4 months. Release of atovaquone (25.9%) was found with PLA nanoparticles at 4 months. Release of both atovaquone (18.9%) and benzylbenzoate (54.2%) was noted with PLAGA nanoparticles from the third month, indicating a disruption of the nanoparticle membrane.
引用
收藏
页码:273 / 281
页数:9
相关论文
共 28 条
[1]   INVITRO RELEASE KINETIC PATTERN OF INDOMETHACIN FROM POLY(D,L-LACTIDE) NANOCAPSULES [J].
AMMOURY, N ;
FESSI, H ;
DEVISSAGUET, JP ;
PUISIEUX, F ;
BENITA, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (09) :763-767
[2]  
AMMOURY N, 1989, STP PHARM, V5, P647
[3]  
*BURR WELLC, 1992, NOV MEPR PACK INS
[4]  
Cauchetier E, 1999, DRUG DEVELOP RES, V47, P155, DOI 10.1002/(SICI)1098-2299(199908)47:4<155::AID-DDR1>3.3.CO
[5]  
2-W
[6]   Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis [J].
Cauchetier, E ;
Paul, M ;
Rivollet, D ;
Fessi, H ;
Astier, A ;
Deniau, M .
INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2000, 30 (06) :777-783
[7]   BIODEGRADABLE PSEUDOLATEXES - THE CHEMICAL-STABILITY OF POLY(D,L-LACTIDE) AND POLY (EPSILON-CAPROLACTONE) NANOPARTICLES IN AQUEOUS-MEDIA [J].
COFFIN, MD ;
MCGINITY, JW .
PHARMACEUTICAL RESEARCH, 1992, 9 (02) :200-205
[8]  
CROFT SL, 1989, LEISHMANIASIS CURREN, P111
[9]   Atovaquone and rifabutine-loaded nanocapsules: Formulation studies [J].
Dalencon, F ;
Amjaud, Y ;
Lafforgue, C ;
Derouin, F ;
Fessi, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (01) :127-130
[10]  
DAVIDSON RN, 1994, Q J MED, V87, P75